Key Points
• Juvenile zebrafish tolerate widespread coagulopathy due to complete ablation of antithrombin III, but develop lethal thrombosis as adults.
• In vivo structure/function analysis of antithrombin III in zebrafish reveals limited roles for heparin binding and anti-IXa/Xa activity.
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Introduction
Venous thrombosis affects approximately 1 in 1,000 individuals, resulting in over 300,000 hospitalizations per year. There are many well described coagulation factor defects which are associated with thrombosis, including deficiencies of the natural anticoagulant proteins, protein C (PROC), protein S (PROS1) and antithrombin III (AT3) 1 . Homozygous deficiency of PROC or PROS1 is exceedingly rare and results in neonatal purpura fulminans in humans 1 . However, mouse knockout models display more severe phenotypes, with neonatal and embryonic loss for PROC and PROS1 deficiency, respectively [2] [3] [4] . Complete loss of AT3 has not been described in humans, and is presumed to be in utero lethal 1 . This is supported by the observation that homozygous deletion of AT3 in mice results in prenatal lethality, with widespread fibrin deposition in the heart and liver 5 . AT3 deficient embryos also exhibit paradoxical hemorrhage, suggesting a consumptive coagulopathy 5 , but this has been difficult to study given the relative inaccessibility of mammalian embryogenesis.
AT3 (also known as SERPINC1) is a serpin (serine protease inhibitor) that regulates many coagulation proteases including thrombin and factors IXa and Xa 6, 7 , and consists of two functional domains. The reactive center loop (RCL) presents the Arg393-Ser394 bond for cleavage, resulting in the formation of a stable inactive AT3-protease complex. The heparin-binding site binds endogenous glycosaminoglycans or infused heparin, acting as a bridge to the protease and inducing allosteric changes in AT3, which accelerates inhibition 6, 7 . Deficiency of AT3 is classified into two categories, type I with reduced plasma antigen levels, and type II with functional defects, but normal AT3 levels 1 . The latter is further subdivided into reactive site, heparin binding, and pleiotropic
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Teleost fish possess highly conserved orthologs of nearly all blood coagulation factors [9] [10] [11] [12] . Zebrafish (Danio rerio) have been most widely used to study hemostasis, demonstrating conservation and function of the structural components of coagulation, including fibrinogen 13, 14 and von Willebrand factor 15, 16 , and the ability to develop thrombosis in response to a laser-induced injury 14, 17 . Embryonic development is external, rapid, and transparent, allowing unfettered access to studies of the circulatory system.
Individual breeding pairs can produce hundreds of offspring with each pairing, facilitating high throughput genetic and small molecule screens 18 .
Recent advances in genome editing technologies have enabled robust platforms for genetic modification [19] [20] [21] . We now report ablation of at3 using zinc finger nucleases (ZFNs). While homozygous mutants recapitulate the consumptive coagulopathy and thrombotic phenotypes of the mouse knockout, the timing demonstrates significant differences. at3 -/-zebrafish are able to tolerate spontaneous thrombosis and rampant disseminated intravascular coagulation (DIC) early in development, but die in adulthood with associated intracardiac thrombosis. Furthermore, using in vivo genetic complementation, we reveal insight into the hemostatic consequences of human AT3
variants.
Methods

Animals
Zebrafish were raised in accordance with animal care guidelines as approved by the University of Michigan Animal Care and Use Committee. Embryos are defined as 0-2 days post fertilization (dpf), and larvae 3-29 dpf.
Targeted mutagenesis using zinc finger nucleases ZFN pairs were designed to target exon 5 of the at3 genomic locus. ZF arrays were constructed using OPEN (Oligomerized Pool ENgineering) as described 22, 23 .
Targeted mutagenesis with the constructed ZFNs was completed essentially as described 19, 24 . ZF arrays were cloned into expression vectors pMLM290 and 292, and transcribed in vitro using T7 mMESSAGE mMACHINE (Ambion, Austin, Texas). 1 nanogram (ng) of each left and right ZFN mRNA were injected into one-cell AB × TL F1 embryos, as described 14 . At 2-3 dpf, 8 morphologically normal embryos were pooled and lysed in buffer (10 mM Tris, pH 8.0, 200 mM NaCl, 10 mM EDTA, 0.5% SDS, 100 μ g/ml Proteinase K) at 50ºC for 2-3 hours, and genomic DNA isolated by phenol:chloroform extraction and ethanol precipitation. PCR of the target site was performed, and products cloned into pCR™-Blunt (Invitrogen, Carlsbad, California).
PCR of 96 colonies was performed using M13 reverse and T7 primers, and products sequenced. The remaining injected F0 embryos were raised to adulthood and crossed to wild type fish. 16-24 F1 embryos from each F0 founder were screened for ZFN-induced mutations by PCR of the target site with a 6-FAM labeled gene-specific primer, after lysis in PCR extraction buffer 24 (10 mM Tris pH 8.0, 2 mM EDTA, 0.2% Triton X-100
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Genotyping of mutant offspring
Fin clip biopsies were obtained from adult fish after anesthesia in tricaine (0.16 mg/ml, Western Chemical Inc., Ferndale, WA), and larvae were euthanized in high dose tricaine (1.6 mg/ml), followed by lysis in PCR extraction buffer 24 . Deletion mutations were detected by PCR and agarose gel electrophoresis (Fig. 1E , bottom). Primers were designed using Primer3 25 and oligonucleotides ordered from IDT (Integrated DNA Technologies, Coralville, Iowa). All oligonucleotide sequences are listed in Supplemental Tables 1 and 2 .
Construction of at3 in vivo expression vectors
Vectors pubi-zat3-EGFP and pubi-hAT3-EGFP were constructed by inserting cDNA sequences under control of the ubi promoter in frame with EGFP in pDestTol2pA2_ubi:EGFP 26 (Supplemental Fig. 1 ). Zebrafish at3 was amplified from total adult cDNA using NcoI tagged primers, and cloned into NcoI digested pDestTol2pA2_ubi:EGFP. Human AT3 was amplified from liver cDNA using primers designed for SLIC (sequence-and ligation-independent cloning), and cloned into NcoI digested pDestTol2pA2_ubi:EGFP as described 27 .
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One-cell injection of at3 expression vectors
Adult blood collection and western blotting
Adult fish blood was collected in EDTA coated microcapillary tubes (Drew Scientific Inc., Dallas, Texas) as described (see Supplemental Methods for a detailed description) 30, 31 . Plasma was obtained by centrifugation at 1,000g for 10 minutes at room temperature, and stored at -80°C. Two µL from pooled wild type or at3 In situ hybridization RNA in situ hybridization was carried out as described 32 . Probes were generated from total zebrafish cDNA using primers with SP6 and T7 overhangs, followed by in vitro transcription with digoxygenin labeled nucleotides.
Thrombin injection
Four milliunits bovine thrombin (Sigma-Aldrich) were retro-orbitally infused 33 into 4 dpf larvae from at3 ∆ 90/+ intercrosses. Phenotypes were collected 2 minutes postinjection by observers blinded to genotype. After phenotyping, larvae were lysed and genotyped (see Supplemental Methods for a detailed description).
Laser-mediated endothelial injury
Endothelial injury was executed using a pulsed nitrogen dye laser and focusing system (MicroPoint, Andor Technology, Belfast, United Kingdom) as described 14, 17 . 3-4 dpf larvae were anesthetized in tricaine, embedded in 0.8% low melt agarose on glass cover slips and visualized on an inverted microscope (Olympus IX71, 40x objective). The posterior cardinal vein (PCV) endothelium was targeted and laser-ablated at the fifth somite distal from the anal pore at power level 18 using 100 pulses. The time to occlusion was recorded up to 2 minutes. Larvae were recovered from agarose and genotyped.
Fibrinogen injection and ε -aminocaproic acid treatment
Offspring from at3 -aminocaproic acid at 2 dpf, and laser injury performed at 60 minutes post-injection or 24 hours post-incubation, respectively, followed by genotyping.
FITC-fibrinogen labeling and infusion
Human fibrinogen was labeled with fluorescein isothiocyanate (FITC, ThermoScientific), PD-10 column purified, and dye-to-protein molar ratio determined by manufacturer's instructions. 8-20 ng of a 1:1 molar ratio of FITC:fibrinogen was infused at 3 dpf.
Embryos were incubated in 50 µg/ml warfarin (Sigma-Aldrich) for 48 hours prior to FITC-fibrinogen infusion, or larvae infused with 1 mg/ml tPA (Alteplase) via retroorbital injection. At 3 dpf, larvae were infused with FITC-fibrinogen and evaluated 1 hour post-injection or post-infusion with tPA, and images were acquired with a CCD camera. Fluorescence intensity was determined either qualitatively by a blinded observer or quantitatively using Scion/ImageJ imaging software 34 . Corrected total cell fluorescence was integrated density after subtraction of background (area selected × mean background fluorescence) 35 .
RNA isolation, generation of cDNA, and RT-PCR
Three dpf larvae were anesthetized in tricaine and biopsied as described 36 37 .
Histological examination
Euthanized adult zebrafish were fixed in 4% buffered formalin overnight at room temperature, bisected in the mid-sagittal plane, embedded in paraffin, and sagittal sections produced at least 50 µm apart. 3-4 µm sections were hematoxylin and eosin stained.
Statistical analysis
Analyses were performed using chi-squared, Mann-Whitney U, Fisher's exact test or two-tailed Student's t tests. Log-rank testing of survival curves was performed using Prism (Graphpad Software, La Jolla, California). For statistical comparisons between individual transgenic rescue experiments, results from homozygous mutants were normalized to the median of their heterozygous clutchmates. P-values were calculated with the Mann-Whitney U test by comparing the normalized data, followed by Bonferroni correction.
Results
Targeted disruption of at3 using genome editing nucleases results in adult lethality in association with massive intracardiac thrombosis
We utilized OPEN (Oligomerized Pool ENgineering) 19, 22, 23 to produce four ZFN pairs designed to cleave exon 5 of the zebrafish at3 genomic locus (zebrafish nomenclature guidelines dictate use of "at3" for the gene, "At3" for protein 38 ). RNA encoding each ZFN pair was injected into the cytoplasm of single cell embryos, with one pair producing somatic mutations ( Table 3 ). at3 (Table 1) with no visible phenotypes.
However, beginning at ~2 months post fertilization (mpf), we observed a significant loss of homozygotes (Table 1) , with ~80% dying between 2-7 mpf (Fig. 1C) . Approximately 5% of at3 -/-mutants had externally visible hemorrhage (Fig. 1D) . RT-PCR indicated reduction of at3 expression in heterozygotes, and absence of expression in homozygous mutants, presumably due to nonsense mediated decay 39 ( Fig. 1E, F ).
To rule out potential off-target ZFN mutations, we injected at3 ∆ 22 incrosses with an at3 cDNA under control of the zebrafish ubiquitin (ubi) promoter (ubi-at3) 26 . After one year, homozygotes displayed significantly greater survival compared to uninjected at3 -/-fish (Fig. 1G ).
Histological examination of surviving at3 -/-fish at 2-3 mpf revealed large intracardiac thrombi in all homozygous mutants examined (n=10), but not in wild type (n=10) or heterozygous mutants (n=10) ( Fig. 2A-D) . Notably, evaluation of a ubi-at3 rescued homozygous at3 type and at3 +/-larvae exhibited vessel occlusion within 2 minutes, but at3 -/-mutants failed to occlude within that time period (Fig. 3A) . To confirm the role of At3 deficiency in this bleeding phenotype, we injected ubi regulated human and zebrafish at3 cDNAs into single cell embryos of wild type and at3 -/-clutchmates, followed by laser injury at 3 dpf. Fifty-two and 83% of human and zebrafish transgene-injected embryos, respectively, demonstrated a time to occlusion of less than 2 minutes (P <0.0001 by the MannWhitney U test, Fig. 3B-C) .
The unexpected prolongation of clotting time in at3 -/-larvae suggested the possibility of differential localization of zebrafish At3 compared to its mammalian ortholog. However, in situ hybridization at 5 dpf revealed strong mRNA expression localized predominantly to the liver, consistent with mouse and human AT3 40, 41 ( Fig. 4A-D ). Minor expression of At3 has been noted in the notochord and neural tube of embryonic day 10.5 mice
42
, while early zebrafish embryos demonstrate weak yolk syncytial layer expression from 16 through 48 hours post fertilization 43 . Alignment with human AT3 revealed that the RCL was highly conserved across species (Supplemental Fig. 2 ). The orthologous P1 arginine was identified (Fig. 4E) , substituted with glycine (zebrafish Arg410Gly, orthologous to human Arg393) and assessed for binding to human thrombin in vitro (Fig. 4F) . While wild type At3 exhibited binding to thrombin and formed a putative thrombin-antithrombin complex (TAT), this interaction was absent in reactions with At3 R410G (Fig. 4F) . To prove that the mutant phenotype was dependent on known serine protease activity, an At3 R410G expressing cDNA was injected into at3 -/-embryos. Consistent with the in vitro binding studies, At3 R410G failed to rescue the at3 -/-larval bleeding phenotype (Fig. 4G) . Taken together, these data strongly suggest that the observed at3 -/-larval phenotype is due to loss of anticoagulant activity.
Hypofibrinogenemia in at3 homozygous mutants explains the increased time to occlusion in larvae
To explain the paradoxical bleeding of at3 -/-larvae, we hypothesized that loss of At3 function results in unregulated procoagulant activity, leading to consumption of fibrinogen, and lack of occlusion after endothelial injury. We infused activated bovine thrombin into larvae to evaluate relative concentrations of clottable fibrinogen at 3-4 dpf 33 . We observed a significant decrease in the number of larvae with severe vascular obstruction (9% of injected at3 -/-vs. 73% and 50% of at3 +/+ and at3 +/-, respectively ( Examination of fibrinogen alpha (fga) and beta (fgb) expression at 3 dpf demonstrated that there were no differences in mRNA accumulation (Fig. 5C ). Infusion with human fibrinogen prior to laser injury at 3 dpf rescued the bleeding phenotype in 52% of at3 -/-larvae ( Fig. 5D , P <0.05 by Mann-Whitney U test when compared to uninjected control). Treatment of larvae prior to laser injury with the fibrinolysis inhibitor ε -aminocaproic acid also rescued the at3 -/-bleeding phenotype ( Fig. 5E , P <0.01).
Hypofibrinogenemia in at3 -/-mutants is secondary to disseminated intravascular coagulation (DIC)
We hypothesized that the mechanism underlying the discrepant adult thrombotic and larval bleeding phenotypes in at3 mutants was DIC, with microscopic fibrin deposition. To identify the location of purported fibrin, human fibrinogen was labeled 44 and infused into at3 +/-intercross progeny.
Widespread PCV fluorescence was observed in at3 homozygous mutant larvae after infusion, but absent in wild type and heterozygous siblings (Figs. 6A-E). Warfarin prevented laser-induced thrombosis in wild type larvae (Supplemental Fig. 5) , and pretreatment of at3 -/-larvae eliminated fluorescence accumulation (Fig. 6F) . Co-injection of tissue plasminogen activator (tPA) partially prevented accumulation, as did post-injection ( Fig. 6G-H) . Taken together, these data support the presence of DIC with consumption of fibrinogen in at3 -/-mutants.
Evaluation of human AT3 mutations in vivo
We examined several additional well-described human AT3 mutations associated with thrombosis, R393H [45] [46] [47] [48] [49] (Fig. 7) . The P1 arginine mutant R393H was unable to reverse the DIC in at3 -/-larvae. Surprisingly, the RCL mutant A404D and heparin binding mutants L99F and K114E all demonstrated significant rescue, although the former was less potent than the latter two. Human AT3 Y253A also reversed the bleeding phenotype and was significantly more efficient when compared to human AT3 (P <0.001).
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Discussion
We report targeted mutagenesis of zebrafish at3 via ZFNs, one class of genome editing nucleases. Our data demonstrate that zebrafish survive complete loss of At3 with rampant DIC in the embryonic and larval periods, but apparently succumb to massive intracardiac thrombosis in adulthood. Concordant with our data, embryonic At3 -/-mutant mice display a consumptive coagulopathy with secondary hemorrhage, although this causes in utero thrombosis and subsequent demise 5 . It is notable that in both the complete mouse knockout and a heparin binding mutant knockin (Arg48Cys) 55 , the heart is one of the most prominent sites of spontaneous thrombosis. The structure of the adult zebrafish heart has been described in detail 56 , and overall cardiovascular development is highly comparable to mammalian and avian species. Taken together, our data support the contention that while the timing of ultimate lethal thrombosis is different between zebrafish and mammals, the underlying mechanisms of the coagulation cascade are conserved.
Our studies indicate that loss of At3 leads to dysregulation of coagulation, resulting in consumption of fibrinogen and prolonged clotting times in at3 homozygous mutant larvae. While there were clearly visible spontaneous macrovascular thrombi in adult fish, injection of fluorescent fibrinogen identified disseminated microvascular thrombi in larvae, the latter consistent with clinical DIC. In patients DIC is characterized by unregulated and excessive thrombin generation, resulting in fibrin formation with secondary plasminogen activation and fibrinolysis 57 . Clinical bleeding and/or thrombosis develops depending on the balance between thrombin and plasmin generation. In at3 58 . They did not observe specific bleeding in homozygous mutant larvae, but did note sporadic adult hemorrhage, both consistent with our data (Fig. 1D) . In contrast, they only detected a partial reduction in survival of homozygous mutants, supporting our data that suggest at3 -/-mutants die from thrombosis rather than hemorrhage.
The observation that spontaneous, non-occlusive thrombosis due to DIC is so well tolerated in fish embryos and larvae raises important questions about the role of the coagulation system in vertebrate development. It is tempting to speculate that additional biological mechanisms may play a role, either through established clotting or other pathways. There may be protective species-specific factors for critical determinants of hemostatic balance, and the ability to perform high-throughput genetic screens in the zebrafish could lead to the identification of novel modifying factors 18 . Another powerful application for zebrafish is small molecule screening, which has led to the rapid clinical development of a novel therapeutic approach for cord blood transplant [59] [60] [61] . Screens for novel anticoagulants or modulators of DIC might also have the potential to lead to innovative therapeutic modalities.
Alignment of human to zebrafish At3 reveals 55% identity and 70% similarity (Supplemental Fig. 2 and ref. 62 ). Since human AT3 rescued the prolonged time to occlusion in our endothelial injury assay, we performed semi-quantitative evaluation of various human mutations and targeted substitutions. Substitution of the RCL P1 arginine (Arg393His) has been identified in several individuals and families with thrombophilia [45] [46] [47] [48] [49] , and has been shown to alter AT3 function in vitro 63 . Arg393His abolished AT3 
Tyr253Ala exhibits enhanced rates of thrombin inhibition in the presence of heparin 54 , which could explain the increased activity. Taken together, these data provide novel insights into AT3 function in vivo. Our approach establishes a rapid and robust new paradigm for validating human genetic variants associated with coagulation disorders, as well as complements biochemical and structure/function studies.
For (D) Rescue of time to laser-induced occlusion by human fibrinogen injection at 3 dpf.
at3
-/-mutant clutchmates were injected with human fibrinogen or bovine serum albumin (BSA). Uninjected (n=13), BSA injection (n=9), and human fibrinogen injection (n=33).
(E) Effects of ε -aminocaproic acid (EACA, 100 mM) pre-treatment on at3 -/-larvae. 
